235 related articles for article (PubMed ID: 19074888)
1. Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation.
Dissanayake SK; Olkhanud PB; O'Connell MP; Carter A; French AD; Camilli TC; Emeche CD; Hewitt KJ; Rosenthal DT; Leotlela PD; Wade MS; Yang SW; Brant L; Nickoloff BJ; Messina JL; Biragyn A; Hoek KS; Taub DD; Longo DL; Sondak VK; Hewitt SM; Weeraratna AT
Cancer Res; 2008 Dec; 68(24):10205-14. PubMed ID: 19074888
[TBL] [Abstract][Full Text] [Related]
2. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma.
O'Connell MP; Fiori JL; Xu M; Carter AD; Frank BP; Camilli TC; French AD; Dissanayake SK; Indig FE; Bernier M; Taub DD; Hewitt SM; Weeraratna AT
Oncogene; 2010 Jan; 29(1):34-44. PubMed ID: 19802008
[TBL] [Abstract][Full Text] [Related]
3. Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration.
Schwartz AL; Malgor R; Dickerson E; Weeraratna AT; Slominski A; Wortsman J; Harii N; Kohn AD; Moon RT; Schwartz FL; Goetz DJ; Kohn LD; McCall KD
Clin Cancer Res; 2009 Jun; 15(12):4114-22. PubMed ID: 19470740
[TBL] [Abstract][Full Text] [Related]
4. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition.
Dissanayake SK; Wade M; Johnson CE; O'Connell MP; Leotlela PD; French AD; Shah KV; Hewitt KJ; Rosenthal DT; Indig FE; Jiang Y; Nickoloff BJ; Taub DD; Trent JM; Moon RT; Bittner M; Weeraratna AT
J Biol Chem; 2007 Jun; 282(23):17259-71. PubMed ID: 17426020
[TBL] [Abstract][Full Text] [Related]
5. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
Cormier JN; Abati A; Fetsch P; Hijazi YM; Rosenberg SA; Marincola FM; Topalian SL
J Immunother; 1998 Jan; 21(1):27-31. PubMed ID: 9456433
[TBL] [Abstract][Full Text] [Related]
7. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
[TBL] [Abstract][Full Text] [Related]
8. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
Marincola FM; Hijazi YM; Fetsch P; Salgaller ML; Rivoltini L; Cormier J; Simonis TB; Duray PH; Herlyn M; Kawakami Y; Rosenberg SA
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):192-205. PubMed ID: 8811494
[TBL] [Abstract][Full Text] [Related]
9. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.
de Vries TJ; Trancikova D; Ruiter DJ; van Muijen GN
Br J Cancer; 1998 Nov; 78(9):1156-61. PubMed ID: 9820172
[TBL] [Abstract][Full Text] [Related]
10. Detecting PKC phosphorylation as part of the Wnt/calcium pathway in cutaneous melanoma.
Dissanayake SK; Weeraratna AT
Methods Mol Biol; 2008; 468():157-72. PubMed ID: 19099253
[TBL] [Abstract][Full Text] [Related]
11. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
12. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.
Weeraratna AT; Jiang Y; Hostetter G; Rosenblatt K; Duray P; Bittner M; Trent JM
Cancer Cell; 2002 Apr; 1(3):279-88. PubMed ID: 12086864
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of spheroid cells from human malignant melanoma cell line WM-266-4.
Na YR; Seok SH; Kim DJ; Han JH; Kim TH; Jung H; Lee BH; Park JH
Tumour Biol; 2009; 30(5-6):300-9. PubMed ID: 19940551
[TBL] [Abstract][Full Text] [Related]
14. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
[TBL] [Abstract][Full Text] [Related]
15. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells.
Ekström EJ; Bergenfelz C; von Bülow V; Serifler F; Carlemalm E; Jönsson G; Andersson T; Leandersson K
Mol Cancer; 2014 Apr; 13():88. PubMed ID: 24766647
[TBL] [Abstract][Full Text] [Related]
16. Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced melanoma cell motility.
Camilli TC; Xu M; O'Connell MP; Chien B; Frank BP; Subaran S; Indig FE; Morin PJ; Hewitt SM; Weeraratna AT
Pigment Cell Melanoma Res; 2011 Feb; 24(1):175-86. PubMed ID: 20955350
[TBL] [Abstract][Full Text] [Related]
17. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
[TBL] [Abstract][Full Text] [Related]
18. [Preparation of the recombinant lentiviral expression vector targeting human Wnt5a gene and its inhibitory effect on melanoma cell invasion].
Zhao Y; Miao Y; Chen X; Wang L; Lu F; Liao W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 May; 30(5):462-5. PubMed ID: 24796738
[TBL] [Abstract][Full Text] [Related]
19. Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells.
O'Connell MP; Fiori JL; Kershner EK; Frank BP; Indig FE; Taub DD; Hoek KS; Weeraratna AT
J Biol Chem; 2009 Oct; 284(42):28704-12. PubMed ID: 19696445
[TBL] [Abstract][Full Text] [Related]
20. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
